Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213305568> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4213305568 endingPage "2034" @default.
- W4213305568 startingPage "2034" @default.
- W4213305568 abstract "Merck's human papillomavirus (HPV) vaccine Gardasil, which was approved by the US Food and Drug Administration (FDA) earlier this month, is that rarest of things: a product with blockbuster potential in rich countries that should also save millions of lives in the developing world. But realising the vaccine's potential will depend on addressing worldwide issues of social and cultural resistance, which are already threatening to slow Gardasil's roll-out in the USA. The main problem critics perceive is this. To be effective, the vaccine must be administered to adolescents before they become sexually active. Indeed, the FDA's decision specifies that girls as young as 9 years old can be treated. But giving recipients full information about the vaccine's purpose will also necessitate teaching them about sex. In some people's eyes, this would undermine abstinence education, and thereby encourage inappropriately young sexual activity. Selection of girls for vaccination, rather than all teenagers, raises further concerns. Such issues of social and cultural acceptability are important to address now, not least because similar arguments will apply to an HIV vaccine, if one is ever developed. To tackle these problems, the Bill & Melinda Gates Foundation announced on June 5 that it will give US$27·7 million to the Programme for Appropriate Technologies in Health to fund research on how best to introduce the new HPV vaccine. This work aims to help smooth introduction of the vaccine to developing countries without the usual decades of delays. But while many of the problems to be studied are unique to the developing world, lessons learned about cultural resistance could, ironically, help smooth the product's implementation in rich nations too. Merck and GlaxoSmithKline—whose own vaccine Cervarix is expected to be submitted for FDA approval this year—therefore have a unique opportunity. By working with PATH to identify cultural, as well as economic, barriers to vaccine roll-out, these companies have the chance to show that enlightened self-interest is a policy position not reserved for governments alone." @default.
- W4213305568 created "2022-02-24" @default.
- W4213305568 creator A5085953656 @default.
- W4213305568 date "2006-06-01" @default.
- W4213305568 modified "2023-09-25" @default.
- W4213305568 title "Rolling out HPV vaccines worldwide" @default.
- W4213305568 doi "https://doi.org/10.1016/s0140-6736(06)68897-1" @default.
- W4213305568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16798365" @default.
- W4213305568 hasPublicationYear "2006" @default.
- W4213305568 type Work @default.
- W4213305568 citedByCount "26" @default.
- W4213305568 countsByYear W42133055682016 @default.
- W4213305568 crossrefType "journal-article" @default.
- W4213305568 hasAuthorship W4213305568A5085953656 @default.
- W4213305568 hasBestOaLocation W42133055681 @default.
- W4213305568 hasConcept C121608353 @default.
- W4213305568 hasConcept C126322002 @default.
- W4213305568 hasConcept C160050368 @default.
- W4213305568 hasConcept C162324750 @default.
- W4213305568 hasConcept C17744445 @default.
- W4213305568 hasConcept C2777265743 @default.
- W4213305568 hasConcept C2778190748 @default.
- W4213305568 hasConcept C2778220009 @default.
- W4213305568 hasConcept C2780195530 @default.
- W4213305568 hasConcept C2908647359 @default.
- W4213305568 hasConcept C3013748606 @default.
- W4213305568 hasConcept C39549134 @default.
- W4213305568 hasConcept C50522688 @default.
- W4213305568 hasConcept C512399662 @default.
- W4213305568 hasConcept C71924100 @default.
- W4213305568 hasConcept C83864248 @default.
- W4213305568 hasConcept C99454951 @default.
- W4213305568 hasConceptScore W4213305568C121608353 @default.
- W4213305568 hasConceptScore W4213305568C126322002 @default.
- W4213305568 hasConceptScore W4213305568C160050368 @default.
- W4213305568 hasConceptScore W4213305568C162324750 @default.
- W4213305568 hasConceptScore W4213305568C17744445 @default.
- W4213305568 hasConceptScore W4213305568C2777265743 @default.
- W4213305568 hasConceptScore W4213305568C2778190748 @default.
- W4213305568 hasConceptScore W4213305568C2778220009 @default.
- W4213305568 hasConceptScore W4213305568C2780195530 @default.
- W4213305568 hasConceptScore W4213305568C2908647359 @default.
- W4213305568 hasConceptScore W4213305568C3013748606 @default.
- W4213305568 hasConceptScore W4213305568C39549134 @default.
- W4213305568 hasConceptScore W4213305568C50522688 @default.
- W4213305568 hasConceptScore W4213305568C512399662 @default.
- W4213305568 hasConceptScore W4213305568C71924100 @default.
- W4213305568 hasConceptScore W4213305568C83864248 @default.
- W4213305568 hasConceptScore W4213305568C99454951 @default.
- W4213305568 hasIssue "9528" @default.
- W4213305568 hasLocation W42133055681 @default.
- W4213305568 hasLocation W42133055682 @default.
- W4213305568 hasOpenAccess W4213305568 @default.
- W4213305568 hasPrimaryLocation W42133055681 @default.
- W4213305568 hasRelatedWork W1966572887 @default.
- W4213305568 hasRelatedWork W2006393849 @default.
- W4213305568 hasRelatedWork W2080029419 @default.
- W4213305568 hasRelatedWork W2206602161 @default.
- W4213305568 hasRelatedWork W2255542004 @default.
- W4213305568 hasRelatedWork W2295279021 @default.
- W4213305568 hasRelatedWork W2748952813 @default.
- W4213305568 hasRelatedWork W2899084033 @default.
- W4213305568 hasRelatedWork W2300824694 @default.
- W4213305568 hasRelatedWork W2724267651 @default.
- W4213305568 hasVolume "367" @default.
- W4213305568 isParatext "false" @default.
- W4213305568 isRetracted "false" @default.
- W4213305568 workType "article" @default.